Aldeyra Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Aldeyra Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($7.69M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($9.77M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($9.93M) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($15.11M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($16.85M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($8.08M) | May 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($8.19M) | Nov 7, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($8.99M) | Aug 1, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($15.62M) | May 2, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($14.55M) | Nov 3, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($17.78M) | Aug 3, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($16.79M) | May 4, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($15.79M) | Nov 10, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($14.94M) | Aug 5, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($11.29M) | May 5, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($8.87M) | Oct 28, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($7.52M) | Aug 5, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($9.87M) | May 6, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($18.72M) | Nov 5, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($13.33M) | Aug 6, 2020 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($8.00M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($10.17M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($10.43M) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($16.14M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($18.01M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($9.39M) | May 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($9.55M) | Nov 7, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($10.34M) | Aug 1, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($16.80M) | May 2, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($14.78M) | Nov 3, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($17.71M) | Aug 3, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($16.48M) | May 4, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($15.44M) | Nov 10, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($14.54M) | Aug 5, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($10.83M) | May 5, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($8.39M) | Oct 28, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($7.11M) | Aug 5, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($9.64M) | May 6, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($19.02M) | Nov 5, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($13.73M) | Aug 6, 2020 |